T1	p 66 97	adults with autistic disorder .
T2	p 109 126	Autistic disorder
T3	p 379 400	persons with autism .
T4	p 491 499	autism .
T5	p 508 564	Thirty adults with autistic disorder completed a 12-week
T6	p 799 810	15 patients
T7	p 1251 1259	level of
T8	p 1283 1298	full-scale IQ .
T9	p 1562 1591	autistic disorder in adults .
T10	p 1703 1741	children and adolescents with autism .
T11	i 23 41	placebo-controlled
T12	i 51 62	fluvoxamine
T13	i 161 172	disturbance
T14	i 580 598	placebo-controlled
T15	i 650 681	inhibitor fluvoxamine maleate .
T16	i 818 837	fluvoxamine-treated
T17	i 907 914	placebo
T18	i 936 947	Fluvoxamine
T19	i 964 971	placebo
T20	i 995 1007	thoughts and
T21	i 1032 1043	maladaptive
T22	i 1130 1136	social
T23	i 1355 1366	fluvoxamine
T24	i 1391 1402	dyskinesias
T25	i 1472 1483	Fluvoxamine
T26	i 1507 1514	placebo
T27	i 1614 1625	fluvoxamine
T28	o 176 182	social
T29	o 279 282	and
T30	o 295 308	Abnormalities
T31	o 682 700	Behavioral ratings
T32	o 984 1016	repetitive thoughts and behavior
T33	o 1032 1052	maladaptive behavior
T34	o 1068 1082	and aggression
T35	o 1119 1126	aspects
T36	o 1130 1148	social relatedness
T37	o 1174 1188	language usage
T38	o 1204 1222	Treatment response
T39	o 1260 1277	autistic behavior
T40	o 1280 1282	or
T41	o 1315 1334	sedation and nausea
T42	o 1376 1448	tolerated . No dyskinesias , adverse cardiovascular events , or seizures